Trial
NCT04878211
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Relapsing Multiple Sclerosis (RMS)
Intervention
Ofatumumab
Why stopped
Trial was terminated for business reasons. There has been no change in the benefit/risk profile of ofatumumab.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-16